| TRADING CENTER |
| Great Call on MGM Mirage! What's Next? - MotleyFool.com | |
| Provenge Action Date Assigned - Analyst Blog - Zacks.com | |
| Dendreon Announces Webcast Presentations at Upcoming Investor Conferences - PR Newswire | |
| FDA says Dendreon's drug application is complete - Reuters | |
| Dendreon Receives FDA Acknowledgement of Complete Response - PR Newswire | |
| Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward ... - PR Newswire | |
Genentech gets FDA bounce - CNNMoney.com | |
Mixed results for big pharma - CNNMoney.com |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 56.85 | 0.30 / 0.53% | 10.87 |
| GILD | Gilead Sciences Inc | 46.59 | 0.33 / 0.71% | 17.99 |
| CELG | Celgene Corporation | 55.97 | -0.56 / -0.99% | 67.43 |
| 2008 Revenue: | $111,000.0 | Headquarters: Seattle, WA |
| Employees: | 198 | CEO: Dr. Mitchell H. Gold, M.D. |
| Net Income: | $-71,644,000.0 | Industry: Biotechnology |
| Market Cap: | $3.2 B | Website: www.dendreon.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| DNDN | 27.26 | +0.08 / +0.29% | 27.18 | 27.88 | 26.80 | Profile Chart News |